Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Anna Maria Rachiglio"'
Autor:
Luigia Turco, Rosa Della Monica, Pasqualina Giordano, Mariella Cuomo, Manuele Biazzo, Baptiste Mateu, Raimondo Di Liello, Bruno Daniele, Nicola Normanno, Antonella De Luca, Anna Maria Rachiglio, Carmela Chiaramonte, Francesca Maria Giugliano, Lorenzo Chiariotti, Giuseppe Catapano, Lorena Coretti, Francesca Lembo
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Oncotherapy can shape intestinal microbiota, which, in turn, may influence therapy effectiveness. Furthermore, microbiome signatures during treatments can be leveraged for the development of personalised therapeutic protocols in cancer treatment base
Externí odkaz:
https://doaj.org/article/498ddb15630d43ecad9d6da11908f2b2
Autor:
Anna Maria Rachiglio, Luca De Sabato, Cristin Roma, Michele Cennamo, Mariano Fiorenza, Daniela Terracciano, Raffaella Pasquale, Francesca Bergantino, Ernesta Cavalcanti, Gerardo Botti, Gabriele Vaccari, Giuseppe Portella, Nicola Normanno
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-10 (2021)
Abstract Background Since the first complete genome sequencing of SARS-CoV-2 in December 2019, more than 550,000 genomes have been submitted into the GISAID database. Sequencing of the SARS-CoV-2 genome might allow identification of variants with inc
Externí odkaz:
https://doaj.org/article/4ec82f5b8ddb419495d0aad76847ed8e
Autor:
Anna Maria Rachiglio, Alessandra Sacco, Laura Forgione, Claudia Esposito, Nicoletta Chicchinelli, Nicola Normanno
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 1, Pp 53-70 (2020)
Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The research on predictive biomarkers in metastatic CRC (m
Externí odkaz:
https://doaj.org/article/924ecdfb2ba3442394c33bdcab876259
Autor:
Alessandro Ottaiano, Stefania Scala, Nicola Normanno, Maria Napolitano, Monica Capozzi, Anna Maria Rachiglio, Cristin Roma, Anna Maria Trotta, Crescenzo D’Alterio, Luigi Portella, Carmela Romano, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Anna Nappi, Salvatore Tafuto, Antonio Avallone, Alfonso De Stefano, Mario Tamburini, Carmine Picone, Antonella Petrillo, Francesco Izzo, Raffaele Palaia, Vittorio Albino, Alfonso Amore, Andrea Belli, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gerardo Botti, Gianfranco De Feo, Paolo Delrio, Guglielmo Nasti
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However,
Externí odkaz:
https://doaj.org/article/c63b96d6390c4ab8b86f568154c6b5fd
Autor:
Cecily P. Vaughn, José Luis Costa, Harriet E. Feilotter, Rosella Petraroli, Varun Bagai, Anna Maria Rachiglio, Federica Zito Marino, Bastiaan Tops, Henriette M. Kurth, Kazuko Sakai, Andrea Mafficini, Roy R. L. Bastien, Anne Reiman, Delphine Le Corre, Alexander Boag, Susan Crocker, Michel Bihl, Astrid Hirschmann, Aldo Scarpa, José Carlos Machado, Hélène Blons, Orla Sheils, Kelli Bramlett, Marjolijn J. L. Ligtenberg, Ian A. Cree, Nicola Normanno, Kazuto Nishio, Pierre Laurent-Puig
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Gene fusion events resulting from chromosomal rearrangements play an important role in initiation of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung tumor predictive b
Externí odkaz:
https://doaj.org/article/b32c4dd2b6ba4fa0b53d8d7901cbaab5
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol 2011, Iss default, Pp 1-9 (2011)
Pietro Carotenuto1, Cristin Roma1, Anna Maria Rachiglio1, Raffaella Pasquale1, Renato Franco2, Giuseppe Antinolfi3, Francovito Piantedosi4, Alfonso Illiano5, Gerardo Botti2, Alessandro Morabito6, Nicola Normanno7, Antonella De Luca71Pharmacogenomic L
Externí odkaz:
https://doaj.org/article/786c88b5f83740f5a44a5da6dc2f2ba6
Autor:
Aldo Scarpa, Katarzyna Sikora, Matteo Fassan, Anna Maria Rachiglio, Rocco Cappellesso, Davide Antonello, Eliana Amato, Andrea Mafficini, Matilde Lambiase, Claudia Esposito, Emilio Bria, Francesca Simonato, Maria Scardoni, Giona Turri, Marco Chilosi, Giampaolo Tortora, Ambrogio Fassina, Nicola Normanno
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80478 (2013)
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents that are already approved for clinical use or are in clinical trials. Therefore, the number of biomarkers that will be needed to assess is expected to
Externí odkaz:
https://doaj.org/article/042dba26cd71478e84302bbe0f5d9039
Autor:
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini
Supplementary Table 3: EPHA2 expression in tumor samples with HSCORE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a802b8696d8d52597033a5f36158547e
https://doi.org/10.1158/1535-7163.22505419
https://doi.org/10.1158/1535-7163.22505419
Autor:
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini
The EPHA2 tyrosine kinase receptor is implicated in tumor progression and targeted therapies resistance. We evaluated EPHA2 as a potential resistance marker to the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in colorecta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3509ddb3be89e10174f92b4e206491f8
https://doi.org/10.1158/1535-7163.c.6538054.v1
https://doi.org/10.1158/1535-7163.c.6538054.v1
Autor:
Erika Martinelli, Fortunato Ciardiello, Maria Sibilia, Giuseppe Signoriello, Daniele Rizzi, Tiziana Pia Latiano, Evaristo Maiello, Virginia Tirino, Anna Maria Rachiglio, Nicola Normanno, Veronica Moreno-Viedma, Mariel C. Paul, Vincenzo Desiderio, Gianpaolo Papaccio, Vincenzo Sforza, Nunzia Matrone, Floriana Morgillo, Carminia Maria Della Corte, Davide Ciardiello, Teresa Troiani, Stefania Napolitano, Valentina Belli, Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini
Supplementary Figure 1. A: Phosphoarray analysis of SW48 and SW48-CR cell lines. B: Silencing of EPHA2 decreases the sensitivity to ALW-II-41-27 in HCT15 and SW48-CR cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1aa7d65ce451b776aca9ce8d725ae9
https://doi.org/10.1158/1535-7163.22505434
https://doi.org/10.1158/1535-7163.22505434